Iodine Uptake After a Low Iodine Diet

NCT05599139 | Recruiting

• 1 other identifier: NL65923.042.18
• Study Type: interventional
• Target: 25
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this clinical trial is to compare the difference in thyroid uptake of a low dose radioactive iodine (10 MBq 123-I or 37 MBq 123-I) in athyreotic patients with differentiated thyroid carcinoma before and after a low iodine diet (LID) of 7 days. The main question it aims to answer is: • What is the difference in iodine uptake before and after a LID of 7 days? Uptake of a low dose of 123-iodine will be measured in participants before and after a low iodine diet of 7 days. Researchers will compare the uptake (%) before and after the LID.

Conditions

Differentiated Thyroid Cancer

Keywords

Low iodine diet; Iodine uptake

Outcome Measures

Primary Outcomes (1)

• Iodine uptake

  Difference in iodine uptake in percentage

  7 days

Study Arms (1)

Low iodine diet

OTHER

Patients recieve a low iodine diet. Consecutive iodine uptake measurements will be made before and after starting this low iodine diet. This study is constructed of only one study arm, and patients will be compared to themselves.

Behavioral: Low iodine diet

Interventions

Low iodine diet BEHAVIORAL

Before ablation and possible subsequent therapy with 131I, patients have to follow a low iodine diet (LID), reducing the iodine intake \< 50 mcg per day and thereby depleting the overall iodine store in the body.

Low iodine diet

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients, men and women above the age of 18 years, have to be diagnosed with DTC and have to follow a LID prior to the 131I ablation therapy according to the Dutch DTC guideline
• Patients have to be fit to adhere to the study protocol
• Patients have to be able to read and understand the Dutch language

You may not qualify if:

• Age \< 18 years
• Patients using amiodarone
• Patients receiving iodinated contrast \< 3 months before the LID
• Pregnancy
• Patients prepared for ablation therapy with rhTSH
• Renal impairment, EGFR \<30ml/min/1,73m2

Sponsors & Collaborators

• University Medical Center Groningen: lead

Study Sites (1)

UMCG

Groningen, Provincie Groningen, 9713GZ, Netherlands

RECRUITING

Study Officials

• Wouter Zandee, Dr.

  University Medical Center Groningen

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Wouter Zandee, Dr.

CONTACT

+31503613731; w.t.zandee@umcg.nl

Mirthe Links, BSc.

CONTACT

+31503610973; m.h.links@umcg.nl

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 25, 2022
• First Posted: October 31, 2022
• Study Start: February 22, 2023
• Primary Completion: March 30, 2026
• Study Completion (Estimated): August 31, 2026
• Last Updated: February 6, 2026

Record last verified: 2026-02

Data Sharing

• IPD Sharing: Will not share

Locations

NL (1)